Roivant Sciences ROIV · NASDAQ
$34.70 +3.49% (+$1.17)
Summary
27 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $1.25B against $107.2M.
- Analysts expect revenue to grow by 531% this fiscal year.
What to watch
- Revenue fell by 36% a year over the last 3 years.
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- It passes only 0 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 19% a year over 5 years. Over the last 3 years it fell by 36% a year. For the next fiscal year analysts expect revenue to grow by 531%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $266.2M.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 14
- Hold 2
- Sell 0
Today's price within the analysts' price targets
The average target of $46.75 is 35% above today's price. 88% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Reportable Segment 100%
By region
The company reports no revenue by region.
Reportable Segment brings in 100% of revenue.
Segments in detail